A Phase 3 interventional study of Brivaracetam in Partial Seizures With or Without Secondary Generalization and Epilepsy, sponsored by UCB Biopharma SRL. Completed at 59 sites in 2 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2025-07-29.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.
Among the 34 studies testing brivaracetam in Epilepsy, this one is the 11th largest by enrollment, is one of 3 that started in 2017, is one of 21 in phase 3, and was the 23rd registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Belgium, Czechia and 8 more countries
Ages 1 mo+
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2017.
This study's enrollment of 207 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 34 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 45th largest by enrollment of the 116 interventional ones that give a count, is one of 8 that started in 2017, is one of 74 in phase 3, and was the 109th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing brivaracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the long-term safety and tolerability of Brivaracetam (BRV) in focal epilepsy subjects with partial seizures and to evaluate the maintenance of efficacy of BRV over time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to this arm will receive open-label Brivaracetam
Drug: Brivaracetam
* Pharmaceutical form: Film-coated tablet * Concentration: 25 mg and 50 mg * Route of administration: Oral use
Also known as: Briviact
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment-emergent AEs (TEAEs) were defined as AEs that had onset on or after the day of first BRV dose in EP0085 study.
Time frame: From Baseline until end of the safety follow up (up to 88.5 months)
Percent Change in Partial Seizure Frequency (PSF) Per 28 Days From Baseline of EP0083 or N01358 to the Evaluation Period for Rollover Study Participants
The seizure frequency was calculated as number of seizures per 28 days. Percent change of 28 day PSF from Baseline was defined as the percentage reduction of 28 day PSF for a designated post-baseline period in EP0085 compared with the Baseline 28 day PSF in the core study. Change in seizure frequency from Baseline was calculated: percent change = (\[Baseline 28 day PSF - Post Baseline 28 day PSF\]/\[Baseline 28 day PSF\]) × 100. For rollovers, the Baseline period was obtained from the core studies of EP0083 and N01358 directly. A negative value in percent change from Baseline indicates a decrease in PSF from Baseline. Evaluation Period values for seizure frequency were calculated from the seizure diary data collected during the Evaluation Period on/after the first BRV administration.
Time frame: Baseline of EP0083 or N01358 and up to 84 months of Evaluation Period
50 Percent (%) Responder Rate in Partial Seizure Frequency Per 28 Days From Baseline of EP0083 or N01358 to the Evaluation Period for Rollover Study Participants
The seizure frequency was calculated as number of seizures per 28 days. 50% responders were defined as a participant with a \>= 50% reduction in seizure frequency from the baseline period over the post-baseline period. Percentages are based on the number of participants who performed the seizure assessment at each time point. Evaluation Period values for seizure frequency were calculated from the seizure diary data collected during the Evaluation Period on/after the first BRV administration.
Time frame: Baseline of EP0083 or N01358 and up to 84 months of Evaluation Period
Percent Change in Partial Seizure Frequency Per 28 Days From Baseline of Directly Enrolled Study Participants to the Evaluation Period
The seizure frequency was calculated as number of seizures per 28 days. For direct enrollers, the Baseline Period was defined as seizure counts collected from 8 weeks prior to the first BRV administration in EP0085. Change in seizure frequency is calculated as the seizure frequency at the evaluation time point minus the seizure frequency at Baseline of directly enrolled participants. A negative value in percent change from Baseline indicates a decrease in PSF from Baseline. Evaluation Period values for seizure frequency were calculated from the seizure diary data collected during the Evaluation Period on/after the first BRV administration.
Time frame: Baseline (8 weeks prior to BRV administration), up to 39 months of Evaluation Period
50 % Responder Rate in Partial Seizure Frequency Per 28 Days Over the Evaluation Period for Directly Enrolled Study Participants
The seizure frequency for directly enrolled participants was calculated as number of seizures per 28 days from 8 weeks prior to BRV administration. 50% responders were defined as a participant with a \>= 50% reduction in seizure frequency from the Baseline Period over the post-baseline period. Percentages are based on the number of participants who performed the seizure assessment at each time point. For direct enrollers, the Baseline Period was defined as seizure counts collected from 8 weeks prior to the first BRV administration in EP0085. Evaluation Period values for seizure frequency were calculated from the seizure diary data collected during the Evaluation Period on/after the first BRV administration.
Time frame: Baseline (8 weeks prior to BRV administration), up to 39 months of Evaluation Period
Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 6 Months During the Evaluation Period for Rollover Study Participants
A study participant was considered seizure free, if no seizure occurred during 6 consecutive months in the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.
Time frame: During the Evaluation Period (up to 84 months)
Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 12 Months During the Evaluation Period for Rollover Study Participants
A study participant was considered seizure free, if no seizure occurred during 12 consecutive months in the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.
Time frame: During the Evaluation Period (up to 84 months)
Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types During the Evaluation Period for Rollover Study Participants
A study participant was considered seizure free (partial, all epileptic seizure), if no seizure occurred during the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.
Time frame: During the Evaluation Period (up to 84 months)
Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 6 Months During the Evaluation Period for Directly Enrolled Study Participants
A study participant was considered seizure free, if no seizure occurred during 6 consecutive months in the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.
Time frame: During the Evaluation Period (up to 39 months)
Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 12 Months During the Evaluation Period for Directly Enrolled Study Participants
A study participant was considered seizure free, if no seizure occurred during 12 consecutive months in the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.
Time frame: During the Evaluation Period (up to 39 months)
Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types During the Evaluation Period for Directly Enrolled Study Participants
A study participant was considered seizure free (partial, all epileptic seizure), if no seizure occurred during the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.
Time frame: During the Evaluation Period (up to 39 months)
The study started to enroll participants in August 2017 and concluded in December 2024.
| Milestone | EP0083 Placebo | EP0083 BRV All | N01379 BRV | Direct Enrollers BRV |
|---|---|---|---|---|
| Started | 54 | 112 | 7 | 34 |
| Evaluation period | 54 | 112 | 7 | 34 |
| Down-titration period | 20 | 32 | 5 | 15 |
| Study drug-free period | 39 | 76 | 5 | 17 |
| Completed | 37 | 74 | 4 | 20 |
| Not completed | 17 | 38 | 3 | 14 |
| Withdrew: Adverse event | 2 | 4 | 0 | 4 |
| Withdrew: Lack of efficacy | 5 | 14 | 1 | 3 |
| Withdrew: Protocol violation | 0 | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 7 | 0 | 4 |
| Withdrew: Investigator's judgment | 1 | 0 | 0 | 0 |
| Withdrew: She wanted to change other therapeutic medication | 1 | 0 | 0 | 0 |
| Withdrew: The subject go abroad and not return | 1 | 0 | 0 | 0 |
| Withdrew: Epilepsy surgery | 0 | 1 | 2 | 0 |
| Withdrew: Subject moved to kanagawa (faraway from clinic) | 0 | 1 | 0 | 0 |
| Withdrew: Request from the sponsor | 0 | 1 | 0 | 0 |
| Withdrew: Subject did not follow procedure or study drug | 0 | 1 | 0 | 0 |
| Withdrew: Subject stopped drug; did not wish to continue | 0 | 1 | 0 | 0 |
| Withdrew: Subjects did not follow procedures or medication | 0 | 1 | 0 | 0 |
| Withdrew: Pregnancy event | 0 | 1 | 0 | 0 |
| Withdrew: Pi's opinion:subject noncompliant with medication | 0 | 1 | 0 | 0 |
| Withdrew: Subjects felt no effect;want to discontinue study | 0 | 1 | 0 | 0 |
| Withdrew: Subjects underweight; intolerant to study drugs | 0 | 1 | 0 | 0 |
| Withdrew: Patient requested to change hospital | 0 | 0 | 0 | 1 |
| Withdrew: Admission to geriatric health facility | 0 | 0 | 0 | 1 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment-emergent AEs (TEAEs) were defined as AEs that had onset on or after the day of first BRV dose in EP0085 study.
| percentage of participants | EP0083 Placebo | EP0083 BRV All | N01379 BRV | Direct Enrollers BRV |
|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) | 88.9 | 95.5 | 100 | 94.1 |
The seizure frequency was calculated as number of seizures per 28 days. Percent change of 28 day PSF from Baseline was defined as the percentage reduction of 28 day PSF for a designated post-baseline period in EP0085 compared with the Baseline 28 day PSF in the core study. Change in seizure frequency from Baseline was calculated: percent change = (\[Baseline 28 day PSF - Post Baseline 28 day PSF\]/\[Baseline 28 day PSF\]) × 100. For rollovers, the Baseline period was obtained from the core studies of EP0083 and N01358 directly. A negative value in percent change from Baseline indicates a decrease in PSF from Baseline. Evaluation Period values for seizure frequency were calculated from the seizure diary data collected during the Evaluation Period on/after the first BRV administration.
| percent change | EP0083 Placebo | EP0083 BRV All | N01379 BRV |
|---|---|---|---|
| Percent Change in Partial Seizure Frequency (PSF) Per 28 Days From Baseline of EP0083 or N01358 to the Evaluation Period for Rollover Study Participants | 60.6 (-87 to 100) | 43.2 (-497 to 100) | 67.0 (-72 to 100) |
The seizure frequency was calculated as number of seizures per 28 days. 50% responders were defined as a participant with a \>= 50% reduction in seizure frequency from the baseline period over the post-baseline period. Percentages are based on the number of participants who performed the seizure assessment at each time point. Evaluation Period values for seizure frequency were calculated from the seizure diary data collected during the Evaluation Period on/after the first BRV administration.
| percentage of responders | EP0083 Placebo | EP0083 BRV All | N01379 BRV |
|---|---|---|---|
| 50 Percent (%) Responder Rate in Partial Seizure Frequency Per 28 Days From Baseline of EP0083 or N01358 to the Evaluation Period for Rollover Study Participants | 66.7 | 47.3 | 57.1 |
The seizure frequency was calculated as number of seizures per 28 days. For direct enrollers, the Baseline Period was defined as seizure counts collected from 8 weeks prior to the first BRV administration in EP0085. Change in seizure frequency is calculated as the seizure frequency at the evaluation time point minus the seizure frequency at Baseline of directly enrolled participants. A negative value in percent change from Baseline indicates a decrease in PSF from Baseline. Evaluation Period values for seizure frequency were calculated from the seizure diary data collected during the Evaluation Period on/after the first BRV administration.
| percent change | Direct Enrollers BRV |
|---|---|
| Percent Change in Partial Seizure Frequency Per 28 Days From Baseline of Directly Enrolled Study Participants to the Evaluation Period | -32.6 (-3691 to 100) |
The seizure frequency for directly enrolled participants was calculated as number of seizures per 28 days from 8 weeks prior to BRV administration. 50% responders were defined as a participant with a \>= 50% reduction in seizure frequency from the Baseline Period over the post-baseline period. Percentages are based on the number of participants who performed the seizure assessment at each time point. For direct enrollers, the Baseline Period was defined as seizure counts collected from 8 weeks prior to the first BRV administration in EP0085. Evaluation Period values for seizure frequency were calculated from the seizure diary data collected during the Evaluation Period on/after the first BRV administration.
| percentage of responders | Direct Enrollers BRV |
|---|---|
| 50 % Responder Rate in Partial Seizure Frequency Per 28 Days Over the Evaluation Period for Directly Enrolled Study Participants | 26.5 |
A study participant was considered seizure free, if no seizure occurred during 6 consecutive months in the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.
| percentage of participants | EP0083 Placebo | EP0083 BRV All | N01379 BRV |
|---|---|---|---|
| Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 6 Months During the Evaluation Period for Rollover Study Participants | 15.4 | 19.8 | 28.6 |
A study participant was considered seizure free, if no seizure occurred during 12 consecutive months in the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.
| percentage of participants | EP0083 Placebo | EP0083 BRV All | N01379 BRV |
|---|---|---|---|
| Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 12 Months During the Evaluation Period for Rollover Study Participants | 8.3 | 14.0 | 33.3 |
A study participant was considered seizure free (partial, all epileptic seizure), if no seizure occurred during the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.
| percentage of participants | EP0083 Placebo | EP0083 BRV All | N01379 BRV |
|---|---|---|---|
| Participants with partial seizure-freedom | 1.9 | 7.1 | 14.3 |
| Participants with all-type seizure-freedom | 1.9 | 7.1 | 14.3 |
A study participant was considered seizure free, if no seizure occurred during 6 consecutive months in the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.
| percentage of participants | Direct Enrollers BRV |
|---|---|
| Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 6 Months During the Evaluation Period for Directly Enrolled Study Participants | 24.1 |
A study participant was considered seizure free, if no seizure occurred during 12 consecutive months in the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.
| percentage of participants | Direct Enrollers BRV |
|---|---|
| Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 12 Months During the Evaluation Period for Directly Enrolled Study Participants | 15.4 |
A study participant was considered seizure free (partial, all epileptic seizure), if no seizure occurred during the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.
| percentage of participants | Direct Enrollers BRV |
|---|---|
| Participants with partial seizure-freedom | 5.9 |
| Participants with all-type seizure-freedom | 5.9 |
Collected over From Baseline until end of the safety follow up (up to 88.5 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EP0083 Placebo | 0/54 (0%) | 6/54 (11.1%) | 41/54 (75.9%) |
| EP0083 BRV All | 0/112 (0%) | 23/112 (20.5%) | 87/112 (77.7%) |
| N01379 BRV | 0/7 (0%) | 5/7 (71.4%) | 6/7 (85.7%) |
| Direct Enrollers BRV | 0/34 (0%) | 6/34 (17.6%) | 27/34 (79.4%) |
| Event | EP0083 Placebo | EP0083 BRV All | N01379 BRV | Direct Enrollers BRV |
|---|---|---|---|---|
| Brain operationSurgical and medical procedures | 1/54 | 0/112 | 2/7 | 0/34 |
| Myocardial infarctionCardiac disorders | 0/54 | 0/112 | 1/7 | 0/34 |
| Synovial cystMusculoskeletal and connective tissue disorders | 0/54 | 0/112 | 1/7 | 0/34 |
| CranioplastySurgical and medical procedures | 0/54 | 0/112 | 1/7 | 0/34 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 0/54 | 0/112 | 0/7 | 2/34 |
| Sinus node dysfunctionCardiac disorders | 0/54 | 0/112 | 0/7 | 1/34 |
| Corona virus infectionInfections and infestations | 0/54 | 0/112 | 0/7 | 1/34 |
| PeritonitisInfections and infestations | 0/54 | 0/112 | 0/7 | 1/34 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 0/54 | 0/112 | 0/7 | 1/34 |
| Scapula fractureInjury, poisoning and procedural complications | 0/54 | 0/112 | 0/7 | 1/34 |
| Event | EP0083 Placebo | EP0083 BRV All | N01379 BRV | Direct Enrollers BRV |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 20/54 | 18/112 | 3/7 | 9/34 |
| DizzinessNervous system disorders | 12/54 | 17/112 | 3/7 | 5/34 |
| Corona virus infectionInfections and infestations | 13/54 | 32/112 | 0/7 | 11/34 |
| Abdominal pain upperGastrointestinal disorders | 2/54 | 6/112 | 2/7 | 2/34 |
| ContusionInjury, poisoning and procedural complications | 7/54 | 11/112 | 2/7 | 4/34 |
| SomnolenceNervous system disorders | 14/54 | 8/112 | 2/7 | 6/34 |
| Upper respiratory tract infectionInfections and infestations | 5/54 | 23/112 | 0/7 | 1/34 |
| PyrexiaGeneral disorders | 9/54 | 21/112 | 1/7 | 6/34 |
| HeadacheNervous system disorders | 10/54 | 21/112 | 0/7 | 3/34 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 5/54 | 11/112 | 1/7 | 5/34 |
Baseline Characteristics refer to the Safety Set (SS) which consisted of all participants who took at least 1 dose of study medication.
| Age, Continuous(years) | EP0083 Placebo | EP0083 BRV All | N01379 BRV | Direct Enrollers BRV | Total |
|---|---|---|---|---|---|
| Mean | 34.5 ± 11.6 | 35.8 ± 13.5 | 40.7 ± 10.9 | 42.2 ± 18.6 | 36.7 ± 14.1 |
| Age, Customized(Participants) | EP0083 Placebo | EP0083 BRV All | N01379 BRV | Direct Enrollers BRV | Total |
|---|---|---|---|---|---|
| 12 - <18 yrs | 2 | 4 | 0 | 1 | 7 |
| 18 - <65 yrs | 52 | 104 | 7 | 29 | 192 |
| 65 - <85 yrs | 0 | 4 | 0 | 3 | 7 |
| >=85 yrs | 0 | 0 | 0 | 1 | 1 |
| Sex: Female, Male(Participants) | EP0083 Placebo | EP0083 BRV All | N01379 BRV | Direct Enrollers BRV | Total |
|---|---|---|---|---|---|
| Female | 32 | 53 | 3 | 19 | 107 |
| Male | 22 | 59 | 4 | 15 | 100 |
| Race/Ethnicity, Customized(Participants) | EP0083 Placebo | EP0083 BRV All | N01379 BRV | Direct Enrollers BRV | Total |
|---|---|---|---|---|---|
| Asian | 54 | 112 | 7 | 34 | 207 |
| Race/Ethnicity, Customized(Participants) | EP0083 Placebo | EP0083 BRV All | N01379 BRV | Direct Enrollers BRV | Total |
|---|---|---|---|---|---|
| Japanese | 32 | 58 | 7 | 34 | 131 |
| Chinese | 22 | 53 | 0 | 0 | 75 |
| Other | 0 | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2017 to primary completion in Dec 2024, 88 months.
Results were first posted in Jul 2025, 7 months after primary completion.
Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 88 months is above that.
Counting every sponsor, half of 85 studies reached it within 48 months; a quarter within 29 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam